Acetaminofen + Codeina Colmed

Quick links to important sections

Acetaminofen + Codeina Colmed

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acetaminofen + Codeina Colmed

The medication Acetaminofen + Codeina Colmed is a foundational pharmaceutical entity defined by its composition and class, formulated to provide comprehensive relief from pain.

Property Description
Active ingredient Acetaminophen and Codeine
Form Solid oral dosage forms (Tablets), Oral solution
Pharmacological class Narcotic Analgesic Combination
Common use Relief of mild to moderately severe pain
Origin Synthetic (Acetaminophen) and Derived Opiate (Codeine)

What Type of Analgesic is Acetaminofen + Codeina Colmed?

Acetaminofen + Codeina Colmed is classified as a combination product belonging to the narcotic analgesic combinations pharmacological group. This designation signifies that the medication utilizes an opioid agent to treat mild to moderately severe pain, a purpose established for this combination. This classification is clinically recognized for its efficacy in situations where non-opioid options alone are insufficient for pain management. The drug is typically manufactured by Colmed, distinguishing it as a regional product with defined market positioning, and is primarily dispensed as solid oral dosage forms, such as tablets.

Composition: Is Acetaminofen + Codeine a Natural or Synthetic Product?

The drug’s structural identity hinges on its two principal active ingredients: Acetaminophen and Codeine. Acetaminophen is categorized as a synthetic compound, while Codeine is naturally derived from the opium poppy, making it an opiate alkaloid, although it is often semi-synthesized for pharmaceutical use. This specific pairing creates the dual composition required to exert both non-opioid and opioid effects simultaneously. This combination achieves an enhanced analgesic effect compared to the single agents alone.

What is the General Therapeutic Purpose of the Combination?

The general therapeutic purpose of this combination product is to provide potent, multi-modal pain relief by addressing discomfort through two separate biochemical pathways. The Acetaminophen component modifies the body’s central pain interpretation and reduces fever. In contrast, the Codeine component, as an opioid agonist, acts to block pain signal transmission. This medication is typically reserved for pain management following minor procedures or injuries, where the level of discomfort necessitates a step-up from standard over-the-counter medication.

Regulatory References

  1. FDA Labeling for Acetaminophen and Codeine

What side effects are possible with Acetaminofen + Codeina Colmed?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety restrictions for Acetaminofen + Codeina Colmed, as documented in official government regulatory sources.


Serious Safety Risks

The medicine carries two primary, life-threatening risks:

  • Acute Liver Failure (Hepatotoxicity): Associated with the acetaminophen component. This risk increases with doses exceeding the maximum daily limit (typically 4,000 mg) or with the use of other acetaminophen-containing products or alcohol. Acute liver failure can lead to the need for a liver transplant or death.
  • Life-Threatening Respiratory Depression: Associated with the codeine component. This involves severely slowed or shallow breathing and is the greatest risk, particularly during therapy initiation or following a dosage increase. This can be fatal.

Common and Other Adverse Reactions

Adverse reactions are classified by frequency and body system:

  • Common Reactions: Drowsiness, lightheadedness, dizziness, sedation, nausea, vomiting, and constipation. These are primarily related to the central nervous system (CNS) and gastrointestinal system.
  • Rare, Serious Reactions: The acetaminophen component has been associated with rare but severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Restrictions and Contraindications

Official regulatory documents enforce strict limitations on use:

  • Pediatric Contraindication: The medicine is contraindicated in all pediatric patients less than 12 years of age and in adolescents younger than 18 years old who have undergone tonsillectomy and/or adenoidectomy.
  • Metabolism Risk: Use is restricted in patients known as ultra-rapid metabolizers of codeine due to the risk of fatal respiratory depression.
  • Abuse and Dependence: The codeine component has a documented risk of addiction, abuse, and misuse, and prolonged use may lead to physical dependence and withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acetaminophen and Codeine combination products details distinct toxicities for each active ingredient, requiring immediate medical attention for suspected overdose.

Documented Manifestations and Outcomes

Overdose symptoms stem from both components. Codeine toxicity is characterized by the opioid triad, including pinpoint pupils, loss of consciousness (stupor or coma), and depression of respiration (slowed or shallow breathing). Acetaminophen overdosage may initially present with non-specific symptoms such as nausea, vomiting, and diaphoresis (sweating).

The most serious outcomes documented are life-threatening respiratory depression and dose-dependent hepatic necrosis (severe liver failure). The risk of fatal overdose is specifically noted following accidental ingestion, particularly by children.

Mandatory Emergency Actions

Regulatory agencies mandate that individuals seek medical help right away or call emergency services immediately for any known or suspected ingestion. This urgent response is necessary because the combined toxicity requires specific interventions. Naloxone is designated to reverse severe opioid effects, and N-acetylcysteine (NAC) is the designated antidote for acetaminophen toxicity. Hospital monitoring and observation are required, as symptoms of liver damage may be delayed by up to 72 hours.

Therapeutic Uses of Acetaminofen + Codeina Colmed

What Acetaminofen + Codeina Colmed Treats: Main Uses and Benefits

The medication is commonly used in situations involving certain distressing symptoms. Specifically, it is used to help relieve pain and may be part of symptomatic management for both pain and fever.

The combination supports symptomatic management for mild to moderately severe pain. It is generally used for conditions associated with acute or disruptive episodes like recovery after minor injuries or dental procedures, and assists with maintaining functional stability when symptoms intensify. The medication is relevant across domains where short-term symptom management is appropriate, addressing domains of symptomatic discomfort, systemic imbalance, and reflexive respiratory irritation (cough).

“This combination is relevant in contexts marked by increased discomfort or tension, and supports patients during episodes of heightened discomfort.”

This combination is considered relevant when symptoms related to physical discomfort co-occur with symptoms related to systemic imbalance (fever), or when sudden breakthrough pain affects patients in palliative care. The combination provides support that helps ease the overall symptom burden in these scenarios.

Quick Fact: Relevant for Managing Symptoms Related to Pain, Fever, and Cough

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility for Acetaminophen and Codeine

Regulatory documents establish strict eligibility criteria for the use of this combination product. Use is primarily established in adults who require pain relief when non-opioid treatments are insufficient.

Absolute Contraindications (Must Not Use):

  • Pediatric Patients: Contraindicated for all children younger than 12 years of age and for patients younger than 18 years of age following tonsillectomy or adenoidectomy.
  • Metabolic Status: Prohibited in patients known to be CYP2D6 ultra-rapid metabolizers.
  • Physiological State: Contraindicated for breastfeeding mothers and patients with severe respiratory depression, severe asthma, or gastrointestinal obstruction.
  • Organ Status: Prohibited in patients with severe hepatic impairment or severe active liver disease.

Conditional or Restricted Use (Use with Caution):

  • Organ Function: Use requires caution in patients with renal impairment or less severe hepatic function impairment.
  • Neurological Conditions: Use requires monitoring in patients with head injury or elevated intracranial pressure.
  • Geriatric Patients: Older adults should be prescribed the medicine with caution due to increased sensitivity and potential for reduced organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Major Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and methylene blue, is strictly contraindicated. This combination product must not be used within 14 days of taking an MAOI. The combination is also contraindicated in children under 12 years of age and in adolescents under 18 years of age following tonsillectomy or adenoidectomy.

Pharmacodynamic and Pharmacokinetic Risks

Interaction Type Interacting Substances/Classes Potential Effect
CNS Depression Alcohol, Benzodiazepines, General Anesthetics, other Opioids Risk of profound sedation, respiratory depression, coma, and death due to additive effects.
Metabolic (CYP2D6) Strong Inhibitors (e.g., Quinidine, Fluoxetine) Decrease in the conversion of Codeine to its active metabolite, Morphine, potentially resulting in reduced pain relief.
Serotonin Syndrome Serotonergic Drugs (e.g., SSRIs, SNRIs) Increased risk of developing Serotonin Syndrome.
Hepatotoxicity Alcohol, other Acetaminophen-containing products Increased risk of acute liver toxicity due to exceeding the maximum daily Acetaminophen dose.

Anticoagulants and Exposure Modifiers

The co-administration with Warfarin or other coumarin derivatives requires cautious monitoring of the International Normalized Ratio (INR) due to the potential for altered anticoagulant activity. Strong CYP3A4 inducers (e.g., Rifampin) can reduce Codeine and Morphine levels, potentially leading to decreased efficacy.

Mechanism of Action

The combination employs a dual-action mechanistic strategy, targeting distinct, yet complementary, signaling pathways to modulate afferent neural signaling and the hypothalamic temperature set point.

Codeine Component: Codeine acts as a prodrug, undergoing metabolism primarily to morphine, which functions as an agonist at central mu-opioid receptors (mu-receptors) in the brain and spinal cord. Binding to these receptors initiates a G-protein-mediated cascade that suppresses the release of nociceptive neurotransmitters, thereby modulating the transmission of afferent signals and adjusting the firing rate of central pain-processing neurons.

Acetaminophen Component: Acetaminophen modulates activity within the cyclooxygenase ( COX) enzyme system, predominantly in the central nervous system. This action results in the inhibition of prostaglandin ( PGE2) synthesis, which are molecular mediators critical for resetting the body's thermoregulatory center in the hypothalamus. This modulation influences the magnitude of central nociceptive signal attenuation and supports the normalization of the hypothalamic temperature set point. This multi-modal pathway interference achieves combined action on both receptor binding and mediator synthesis, affecting dysregulated afferent nociceptive input.

Dosage and Administration Information

Acetaminofen with Codeine is designated for oral administration only, available as both solid oral forms (tablets) and liquid oral solutions.

Standard Administration and Frequency

The standard regimen for adults generally involves taking one to two tablets or 15 milliliters of oral solution per dose. This medication is typically used on an as-needed (PRN) basis, with doses separated by a minimum of four hours. A critical usage principle is adherence to the maximum daily dose for the Acetaminophen component, which must not exceed 4,000 mg from all sources. Usage is typically limited to the shortest duration consistent with the acute need. If the liquid formulation is used, the suspension must be shaken well before measurement, and the dose should be accurately determined using a calibrated measuring device. The medication may be taken with food if it causes stomach upset.

Population-Specific Use

The combination product is contraindicated for use in children under 12 years of age. For older adults, administration requires a modified approach where the dosage is titrated slowly and the patient is closely observed. Furthermore, patients with renal impairment may require an extended interval between doses, sometimes up to six or eight hours depending on the degree of kidney function. If a dose is missed, the standard procedure is to skip the missed dose if it is almost time for the next scheduled dose, and to never double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acetaminofen + Codeina Colmed

Research for this combination product has focused on evaluating its role in exploring changes related to pain and, to a lesser extent, outcomes related to systemic or functional imbalance such as cough. The evidence is derived primarily from formal clinical trials and comprehensive scientific reviews that examined outcomes related to physical discomfort and systemic or functional imbalance.


Evidence for Use in Mild to Moderately Severe Acute Pain

The combination product was studied for its role in studies examining changes related to acute or disruptive episodes of pain, which includes discomfort that follows procedures or injuries. The most compelling evidence was observed in multiple short-term, single-dose Randomized Controlled Trials (RCTs). The findings from these trials were subsequently examined through scientific Systematic Reviews to pool the data.

In these studies, the research explored short-term symptom changes in adult populations experiencing conditions involving periods of heightened symptoms. Researchers monitored measurements of pain intensity changes on standardized scales and the time until patients needed additional pain medication (rescue medication). The findings describe patterns observed in the studies over the few hours immediately following administration. This structure of evidence contributes to the broader evidence landscape for short-term symptom patterns.


Research Structure for Symptomatic Cough Management

The combination was studied for outcomes related to outcomes linked to inflammatory or irritative states, such as cough. This evidence is associated with the established properties of the Codeine component itself, which was studied for outcomes related to reflexive respiratory irritation.

Scientific sources indicate that the certainty remains low for the combination product in this specific context. Dedicated, high-quality Randomized Controlled Trials of the specific Acetaminofen + Codeina combination for cough relief are not consistently summarized in modern regulatory reviews, pointing to an area where more targeted research is needed.


What the Research Indicates as Uncertain or Limited

A transparent review of the clinical research highlights several important limitations and areas where data remain uncertain:

  • Duration of Effect: The evidence is primarily derived from short-term, single-dose studies, and the data for long-term effects or long-term consistency remain limited.
  • Variability in Response: Scientific findings indicate that the medication's effects can vary significantly between individuals. This variability was associated with differences in how the body processes the codeine component.
  • Study Comparisons: In certain acute pain settings, research exploring how the combination compared to non-opioid medications findings were mixed.
  • Special Populations: The results apply only to the populations studied, and subgroup findings are uncertain due to variability in individual processing of codeine.

Key Studies & References

  1. Systematic Review on Treatments for Acute Pain: Surveillance Report 3 (Agency for Healthcare Research and Quality - AHRQ)
  2. ACETAMINOPHEN AND CODEINE PHOSPHATE tablet (Official FDA/DailyMed Label)
  3. Codeine response (NIH Genetic Testing Registry - Variability in Codeine Metabolism)
  4. Medications Containing Low-Dose Codeine for the Treatment of Pain and Coughs (CADTH Summary)

Frequently Asked Questions (FAQ)

Common questions about Acetaminofen + Codeina Colmed (FAQ)

Q: How long can the pain-relieving effects of a single dose be expected to last?

According to official product information, the medication is generally used on an as-needed basis, and regulatory documents specify that doses should be separated by a minimum of four to six hours. This interval helps inform the expected period of the medicine's effect before the next dose may be considered.

Q: What is the general guidance on the maximum number of consecutive days this medicine should be used?

Official guidance emphasizes that the medication is intended for the shortest duration consistent with the acute pain need. This principle is focused on limiting overall exposure to the medication. Regulatory documents prioritize this principle rather than prescribing a specific maximum number of consecutive days.

Q: Is Acetaminofen + Codeina Colmed a controlled substance?

Yes, because of the codeine component, regulatory documents classify this combination product as a controlled substance in the United States. This designation signifies that the drug has an accepted medical use but also carries a potential for abuse or dependence.

Q: Is it possible to have an allergic reaction to Acetaminofen + Codeina Colmed ingredients?

Official product information advises that the medication is generally restricted for use by those who have known allergies to codeine, other opioid medicines, or any other ingredients in the product. This indicates that hypersensitivity reactions are a possibility.

Q: What kind of mental changes are reported in association with codeine use?

The codeine component is associated with central nervous system effects, and official documents commonly list symptoms such as drowsiness, sedation, dizziness, and lightheadedness. In some instances, official product information also mentions the possibility of broader mental changes like confusion or delirium.

Q: How quickly does the pain relief from Acetaminofen + Codeina Colmed usually begin?

Authoritative sources describe the onset of action for the immediate-release tablet form as generally occurring within 15 to 60 minutes after administration. It is noted that individual results can vary depending on how a person processes the codeine component.

Q: What signs might indicate a person is developing a tolerance to the Codeina ingredient?

Official regulatory labeling indicates that if the medication is used for a prolonged period, the body may develop a tolerance to the effects of codeine. This change is officially described as being indicated when a patient requires a higher dose of the medication to achieve the same analgesic effect.

Q: What over-the-counter (OTC) medicines should be checked for hidden acetaminophen?

Regulatory warnings caution that users should check the labels of all other medications for the presence of acetaminophen, which is used in many common non-prescription products. This is necessary to avoid exceeding the overall maximum daily intake limit.

Q: Is it safe to use other pain relievers like ibuprofen or naproxen alongside this medicine?

Official product labeling does not typically contraindicate the concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen or naproxen. However, since regulatory documents focus on specific drug-to-drug interactions, official labeling suggests that the use of any additional pain relievers be discussed with a healthcare provider.

Q: What is the official information regarding the use of this drug during pregnancy?

Official documentation states that prolonged use of any opioid medication during pregnancy carries a risk of causing Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn baby. The official recommendation is that the medication be used only if the potential benefit is assessed to clearly outweigh the risk to the fetus.

Q: Are there different strengths of Acetaminofen + Codeina Colmed available, and why?

Yes, this combination product is officially approved and available in multiple fixed-dose strengths. This variety of strengths is provided to allow for flexibility in administration, enabling healthcare providers to select a product appropriate to the specific level of pain relief needed.

Q: What is the difference between codeine and other stronger opioids in official descriptions?

Codeine is typically intended for mild to moderately severe pain. It is described in regulatory contexts as an opioid prodrug that is metabolized into the active form, morphine. Other prescription opioids are often noted in their official descriptions for use in more severe pain and possess different potency and processing profiles in the body.

Q: Is Acetaminofen + Codeina Colmed also used to treat cough or diarrhea?

While the codeine component itself has properties that can suppress cough or reduce intestinal movement (a factor that leads to constipation), the combination product is officially indicated by government agencies only for the relief of pain.

Q: Can the use of Acetaminofen + Codeina Colmed cause rebound headaches or increased pain sensitivity?

Opioid-containing combination analgesics, like this one, have been associated with a risk of developing Medication-Overuse Headaches (MOH) or increased pain sensitivity. This risk is typically described in official reviews as occurring in patients who are susceptible to the condition and who overuse the medication.

Q: What are the signs of a serious, but rare, adrenal gland problem associated with opioid use?

The long-term use of opioid medications may be associated with the development of a serious, but rare, condition known as adrenal insufficiency. Symptoms of this condition, as listed in official medical references, can include persistent nausea, vomiting, loss of appetite, fatigue, dizziness, and generalized weakness.

Q: Does this medication have an effect on sexual function or fertility as an opioid?

Official regulatory warnings indicate that the use of this opioid combination medication may result in decreased fertility in both male and female patients. The product information is also associated with descriptions of decreased sexual desire and difficulty achieving or maintaining an erection.

Q: How is the safety of this drug monitored by government agencies?

The ongoing safety of the medication is monitored primarily through post-marketing surveillance programs, such as the FDA's MedWatch. These systems allow both consumers and healthcare professionals to voluntarily report any adverse events or medication errors to the regulatory agency for review.

Q: Can this medication affect the results of certain laboratory tests?

Yes, regulatory documentation indicates that the acetaminophen component of this medicine may interfere with the results of certain laboratory tests. Specifically, it can produce false-positive test results for substances such as urinary 5-hydroxyindoleacetic acid.

Q: Why is checking the expiration date important for this specific type of medicine?

Checking the expiration date is important to ensure that the medication retains its full strength and quality as described by the manufacturer. Using medications past this date may lead to reduced effectiveness or, in some cases, the formation of degraded compounds.

How should Acetaminofen + Codeina Colmed be stored and disposed of?

Storage and Disposal Requirements for Acetaminophen and Codeine

Acetaminophen and Codeine Phosphate tablets must be stored under specific regulatory conditions to maintain stability and ensure safety.

Official Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature, 20^circC to 25^circC (68^circF to 77^circF).
Protection Keep the container tightly closed and protect the medication from excess heat and moisture.
Child Safety Store the tablets securely and keep them strictly out of the sight and reach of children.

Official Disposal Instructions

Unused or expired medication should be disposed of using an authorized drug take-back program. If a take-back program is not available, the tablets must be removed from the container, mixed with an undesirable substance (such as dirt or coffee grounds), and placed in a sealed bag for disposal in the household trash. This product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acetaminofen + Codeina Colmed found in:

A-Z Index: